Google Cloud to Host Second-Annual Cancer AI Symposium in New York City
Leading organizations, researchers, clinicians, and venture capital firms converge to accelerate AI-driven innovation across the cancer continuum NEW YORK, Oct....
Pharmaceutical
MOOV Expands to Los Angeles With Acquisition of RenewMe
Physician-led wellness brand brings its evidence-based longevity and recovery model to downtown LA. LOS ANGELES, CA / ACCESS Newswire /...
AGFA HealthCare at RSNA 2025: Empowering Clinicians. Elevating Enterprise Imaging
At this year's RSNA 2025 Annual Meeting (November 30 - December 4, McCormick Place, Booth #2565), AGFA HealthCare will highlight...
Medical Care Technologies Inc. (OTC Pink:MDCE) Ranked #1 on InvestorHub Breakout Boards as Company Expands Across Technology and Collectibles Divisions
MESA, ARIZONA / ACCESS Newswire / October 30, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified holding company...
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company...
Entero’s Reinvention Gives the Grid, AI, and Investors Exactly What They’re After: Power and Value (NASDAQ: ENTO)
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics (NASDAQ:ENTO) has just made one of the...
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release...
Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution
Ritedose receives FDA approval for Tobramycin Tobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the...
Evaxion raises $7.2 million, extending cash runway to second half of 2027
Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross...
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor...
ORYZON to Participate in Upcoming Events in November
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05%...
Veru Announces Pricing of $25 Million Public Offering
MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...